Study of mosunetuzumab and zanubrutinib for relapsed follicular lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two targeted drugs, mosunetuzumab and zanubrutinib, for people with follicular lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have follicular lymphoma (a type of B-cell lymphoma) that has returned or not responded to at least one but no more than three prior treatments.
- You need treatment for your lymphoma now.
- You are able to swallow pills and have adequate kidney, liver, and blood cell function.
- You have not had a BTK inhibitor or a certain type of immunotherapy called a bispecific antibody before.
- You agree to use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies mosunetuzumab alone or combined with zanubrutinib to treat people with follicular lymphoma that is advanced or causing problems. It’s meant to see which approach works better and is safe for long-term treatment.
This study tests two new drugs combined together to treat follicular lymphoma (a slow-growing blood cancer). The trial enrolls patients who have never been treated, those with limited disease who want active treatment, and those whose cancer came back or didn't respond to prior therapy.
This Phase 2 study tests whether mosunetuzumab, added to lenalidomide, can treat people who have not yet received lymphoma medicines. It’s for follicular lymphoma or marginal zone lymphoma and may help shrink tumors and improve control of the disease.
This trial tests a new drug, mosunetuzumab, given as a shot under the skin for people with a slow-growing type of lymphoma (follicular lymphoma) that has not yet been treated and is not causing heavy symptoms or large tumor masses.
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.